BidaskClub Downgrades Pulse Biosciences (PLSE) to Sell

Share on StockTwits

Pulse Biosciences (NASDAQ:PLSE) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Shares of NASDAQ:PLSE opened at $16.40 on Friday. Pulse Biosciences has a one year low of $9.81 and a one year high of $39.50.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, May 8th. The company reported ($0.51) EPS for the quarter.

In related news, Director Robert W. Duggan acquired 21,353 shares of the business’s stock in a transaction dated Friday, May 11th. The stock was bought at an average price of $23.16 per share, for a total transaction of $494,535.48. Following the transaction, the director now owns 5,862,422 shares of the company’s stock, valued at $135,773,693.52. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 39.30% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in shares of Pulse Biosciences during the 4th quarter valued at $7,975,000. Deutsche Bank AG lifted its holdings in shares of Pulse Biosciences by 141.3% in the fourth quarter. Deutsche Bank AG now owns 20,305 shares of the company’s stock valued at $478,000 after purchasing an additional 11,890 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Pulse Biosciences in the fourth quarter valued at $290,000. Alliancebernstein L.P. purchased a new stake in shares of Pulse Biosciences in the fourth quarter valued at $248,000. Finally, Brown Advisory Inc. purchased a new stake in shares of Pulse Biosciences in the fourth quarter valued at $248,000. Institutional investors own 8.96% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Gap Inc  Expected to Announce Quarterly Sales of $3.98 Billion
Gap Inc Expected to Announce Quarterly Sales of $3.98 Billion
Sinovac Biotech  Given Daily Media Impact Rating of -0.02
Sinovac Biotech Given Daily Media Impact Rating of -0.02
Limoneira  Receives Daily News Sentiment Rating of 0.06
Limoneira Receives Daily News Sentiment Rating of 0.06
Motorola Solutions  Hits New 1-Year High at $121.69
Motorola Solutions Hits New 1-Year High at $121.69
Vince  Hits New 52-Week High at $20.35
Vince Hits New 52-Week High at $20.35
Brokerages Anticipate First Industrial Realty Trust, Inc.  Will Post Earnings of $0.40 Per Share
Brokerages Anticipate First Industrial Realty Trust, Inc. Will Post Earnings of $0.40 Per Share


© 2006-2018 Ticker Report. Google+.